Researchers analyzing more than 830,000 brain immune cells from 1,607 donors have discovered a protective microglial subtype that expands as Alzheimer’s disease progresses. Published in Nature Genetics, the work maps six subclasses and 13 distinct subtypes of myeloid cells, revealing the molecular signaling pathway that enables these cells to defend human brain tissue.
Mapping the Brain’s Immune System at Unprecedented Scale
Aging stands as a risk factor for dementia, yet the underlying cellular mechanisms driving neurodegeneration have remained difficult to fully capture.
To address this blind spot, investigators from the Icahn School of Medicine at Mount Sinai launched a massive profiling effort. Led by Donghoon Lee and Panos Roussos, the team examined myeloid-origin immune cells extracted from the prefrontal cortex of 1,607 donors. By analyzing over 830,000 individual cells spanning various ages and disease stages, the researchers constructed the most comprehensive cellular reference of its kind to date.
“Our study provides the clearest picture yet of how the brain’s immune cells adapt during aging and Alzheimer’s disease.”
Donghoon Lee, Assistant Professor of Genetics and Genomic Sciences and Psychiatry at Mount Sinai
A Protective Microglial Subtype Emerges in Alzheimer’s Progression
Microglia serve as the resident immune cells of the brain, working alongside perivascular macrophages to modulate local immune responses. Within the massive dataset, the research team identified six distinct subclasses encompassing 13 unique subtypes of myeloid cells. Rather than portraying a uniform inflammatory response, the data revealed that a specialized disease-associated subtype of microglia actually multiplies as Alzheimer’s disease advances.
Instead of accelerating tissue damage, these specialized cells ramp up their capacity to engulf and clear harmful material from the brain. The analysis showed that this beneficial microglial activity relies directly on a specific molecular signaling pathway involving the proteins TREM2, MITF, and GPNMB. Experiments across both human tissue and animal models confirmed that the protective function of these cells depends entirely on intact TREM2 signaling.
This discovery helps clarify why specific genetic variants in immune-related genes such as TREM2 and APOE elevate an individual’s susceptibility to Alzheimer’s disease. Pinpointing these pathways offers researchers concrete cellular targets for future therapeutic interventions.
Broader Implications for Neurodegenerative Therapies
The identification of a naturally occurring defense mechanism shifts focus away from traditional therapeutic approaches that target amyloid plaques in isolation. By understanding how the brain attempts to protect itself through specialized immune cell plasticity, drug developers gain a new roadmap for creating treatments designed to strengthen these native defenses.
By identifying the specific immune cells that appear to protect the brain—and the molecular signals they rely on—we have uncovered potential new targets for therapies aimed at slowing Alzheimer’s disease progression,
Lee explained. While parallel research indicates that other mechanisms—such as the transport of toxic Tau protein via Arc proteins studied in mouse models—also contribute to neurodegeneration, the Mount Sinai findings provide a foundational atlas for harnessing the brain’s internal immune architecture to alter the course of disease.
Worth a look
- Colombia Earthquake Death Toll Reaches 181 As New President Faces Crisis
- Sri Lanka: Dengue cases top 90,000, Syphilis cases up in 2025
- Chronic Kidney Disease Risk After Nephrectomy: What to Know (newsy-today.com)
- SANDI Diffusion Modeling Reveals Striatal Abnormalities in Huntington’s Disease (archynewsy.com)
